548760-12-9Relevant academic research and scientific papers
Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: A novel series of CB1 receptor antagonists
Bostroem, Jonas,Berggren, Kristina,Elebring, Thomas,Greasley, Peter J.,Wilstermann, Michael
, p. 4077 - 4084 (2008/03/12)
A scaffold hopping approach has been exploited to design a novel class of cannabinoid (CB1) receptor antagonists for the treatment of obesity. On the basis of shape-complementarity and synthetic feasibility the central fragment, a methylpyrazole, in Rimonabant was replaced by a pyrazine. The synthesis and CB1 antagonistic activities of a new series of 5,6-diaryl-pyrazine-2-amide derivatives are described. Several compounds showed antagonist potency below 10 nM for the CB1 receptor.
Discovery of pyrazine carboxamide CB1 antagonists: The introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series
Ellsworth, Bruce A.,Wang, Ying,Zhu, Yeheng,Pendri, Annapurna,Gerritz, Samuel W.,Sun, Chongqing,Carlson, Kenneth E.,Kang, Liya,Baska, Rose A.,Yang, Yifan,Huang, Qi,Burford, Neil T.,Cullen, Mary Jane,Johnghar, Susan,Behnia, Kamelia,Pelleymounter, Mary Ann,Washburn, William N.,Ewing, William R.
, p. 3978 - 3982 (2008/02/07)
Structure-activity relationships for a series of pyrazine carboxamide CB1 antagonists are reported. Pharmaceutical properties of the series are improved via inclusion of hydroxyl-containing sidechains. This structural modification sufficiently improved ADME properties of an orally inactive series such that food intake reduction was achieved in rat feeding models. Compound 35 elicits a 46% reduction in food intake in ad libidum fed rats 4-h post-dose.
